Flixotide Evohaler inhalation aerosol 125 μg / dose, 120 doses — Made in France — Free Delivery

Product description

Aerosol for inhalation (dosed) "Flixotide ™ Evohaler ™" is used for the prophylactic treatment of bronchial asthma:

adults:

• mild asthma: patients who need periodic symptomatic treatment with bronchodilators daily;
• moderate asthma: patients with unstable asthma or worsening of the condition on the background of existing preventive therapy or therapy with only bronchodilators;
• severe asthma: patients with severe chronic asthma and patients dependent on systemic corticosteroids for adequate control of symptoms (after starting the use of inhaled fluticasone propionate, many of these patients will be able to significantly reduce or completely abandon the oral use of corticosteroids);

children:

• prophylactic anti-asthma treatment, including in the case when control of asthma symptoms has not been achieved against the background of treatment with other anti-asthma drugs.

Compound

The active ingredient is fluticasone propionate (one dose contains 125 μg of fluticasone propionate).

The excipient is the propellant HFA 134a.

Contraindications

Hypersensitivity to any component of the drug.

Mode of application

The drug is intended for oral inhalation use only.

For patients who find it difficult to synchronize their breathing with pressing the valve, it is recommended to use a spacer (a device to facilitate the administration of inhaled drugs).

Patients should be informed that inhaled flixotide should be used regularly to prevent the disease, even in the absence of asthma attacks. The onset of therapeutic action is observed after 4-7 days.

In the event of a decrease in the effectiveness of short-acting bronchodilators or the need for their frequent use, the patient should consult a doctor.

The physician should keep in mind that fluticasone propionate is effective at half the dose of other inhaled corticosteroids. For example, 100 mcg of fluticasone propionate is roughly equivalent to a 200 mcg dose of beclomethasone dipropionate (which contains freon) or budesonide.

The initial dose should be appropriate for the severity of the disease. The dosage can be increased until control is achieved or decreased to the minimum effective dose that allows effective control of the disease.

Adults and children over 16 years old: 100-1000 mcg 2 times a day, usually two inhalations 2 times a day.

Due to the risk of systemic effects, doses of more than 500 mcg 2 times a day can only be prescribed to adult patients with severe bronchial asthma, when an improvement in pulmonary function and / or control of symptoms is expected, or a decrease in the use of oral corticosteroids.

Typical starting dose for adults. For patients with mild asthma, the typical starting dose is 100 mcg 2 times a day. For moderate asthma of moderate severity and severe persistent asthma, the initial dose can be from 250 to 500 mcg 2 times a day. If necessary, you can prescribe doses of more than 1000 mcg 2 times a day. Such doses can only be prescribed by a specialist in the treatment of patients with asthma.

The dosage should be reduced to the lowest effective dose that allows effective disease control to be established.

Typical starting dose for children from 4 years of age: 50-100 mcg 2 times a day.

In many children, asthma is well controlled with doses of 50-100 mcg 2 times a day.

For children for whom this dose is insufficient, improvement can be achieved by increasing the dose to 200 mcg 2 times a day. The maximum dose for children is 200 mcg 2 times a day.

The dosage should be reduced to the lowest effective dose that allows effective disease control to be established.

Doses of more than 1000 mcg (500 mcg 2 times a day) should be administered through a spacer to reduce adverse reactions from the mouth and throat.

Application features

Pregnant

Experience with use during pregnancy in humans is limited. When deciding on the appointment of the drug during this period, it is necessary to weigh the expected benefits for the mother and the potential risk to the fetus. The results of a retrospective epidemiological study did not reveal an increased risk of major congenital malformations after exposure to fluticasone propionate during the first trimester of pregnancy compared with other inhaled corticosteroids.

It is currently not established whether fluticasone propionate passes into breast milk, however, based on the pharmacological profile of the drug, this is unlikely. It is possible to use the drug during breastfeeding only when the expected benefit to the mother outweighs the potential risk to the fetus.

Children

For use in children over 4 years of age.

Drivers

Any effect on the reaction rate when driving or driving other mechanisms is unlikely.

Overdose

When using the drug "Flixotide ™ Evohaler ™" in doses higher than recommended, an acute overdose may occur, which manifests itself in a temporary suppression of adrenal function. This does not require emergency treatment, since the function of the adrenal cortex is restored after a few days, which is confirmed by measuring the level of cortisol in the blood plasma.

However, when using doses exceeding the recommended ones, for a long time, significant suppression of adrenal function can be observed. There have been isolated reports of acute adrenal crises that occurred in children who were treated above the recommended dose (usually 1000 mcg and above) for a long time (several months or years). Symptoms observed during this included hypokalemia and sequelae of loss of consciousness and / or convulsions. Situations that can provoke an acute adrenal crisis include trauma, surgery, infections, or a sharp dose reduction.

In case of overdose, therapy can be continued at the doses necessary to control asthma symptoms. Patients who are treated with doses higher than recommended should be under the special supervision of a physician, and the dose of the drug for them should be reduced gradually.

Side effects

Infections and invasions: very often - candidiasis of the oral cavity and pharynx; often - patients with COPD may develop pneumonia.

Respiratory system and chest: often - hoarseness.

Skin and subcutaneous tissue: often bruising.

Storage conditions

Store at a temperature not exceeding 30 ° C, out of the reach of children. Do not freeze. Protect from direct sunlight.

Immediately after use, close the mouthpiece with the cap, gently pressing it until you hear a click.

Shelf life is 2 years.